Literature DB >> 11862380

Clozapine can induce high dopamine D(2) receptor occupancy in vivo.

Tetsuya Suhara1, Takashi Okauchi, Yasuhiko Sudo, Akihiro Takano, Koichi Kawabe, Jun Maeda, Shitij Kapur.   

Abstract

RATIONALE: Clozapine is a unique antipsychotic with very low propensity to cause motor side effects. In contrast to most other antipsychotics that block more than 70% of dopamine D(2) receptors at therapeutic doses, clozapine occupies less than 70%. Furthermore, even at maximum occupancy, 70% is not exceeded. Several mechanisms have been proposed as explanations for this low D(2) receptor occupancy, but clear evidence is limited.
OBJECTIVES: In patient studies the data are limited by the dose-range that can be safely used; therefore, the aims of this study were to examine the maximum occupancy of dopamine D(2) receptors with up to 5.0 mg/kg of bolus injection of clozapine to non-human primates and to measure the time course of occupancy.
METHODS: PET examination with [(11)C]raclopride was performed to measure the dopamine D(2) receptor occupancy in the striatum of two monkeys after the bolus injection of 0.2-5.0 mg/kg clozapine. [(11)C]raclopride was injected sequentially to follow the time course of occupancy up to 7 h after the clozapine injection.
RESULTS: Dopamine D(2) receptor occupancy reached up to 83% after 5.0 mg/kg clozapine injection. Occupancy decreased with a half-life of 7.22 h after 5.0 mg/kg clozapine and 5.25 h after 1.0 and 2.0 mg/kg clozapine.
CONCLUSIONS: Clozapine could occupy a high proportion of dopamine D(2) receptors. The time course of occupancy was relatively fast, with a half-life of several hours.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11862380     DOI: 10.1007/s00213-001-0967-0

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  6 in total

Review 1.  Modern antipsychotic drugs: a critical overview.

Authors:  David M Gardner; Ross J Baldessarini; Paul Waraich
Journal:  CMAJ       Date:  2005-06-21       Impact factor: 8.262

2.  Subtyping Schizophrenia by Treatment Response: Antipsychotic Development and the Central Role of Positive Symptoms.

Authors:  Jimmy Lee; Hiroyoshi Takeuchi; Gagan Fervaha; Gwen Li Sin; George Foussias; Ofer Agid; Saeed Farooq; Gary Remington
Journal:  Can J Psychiatry       Date:  2015-11       Impact factor: 4.356

3.  Dopamine D₂/₃ occupancy of ziprasidone across a day: a within-subject PET study.

Authors:  Takefumi Suzuki; Ariel Graff-Guerrero; Hiroyuki Uchida; Gary Remington; Fernando Caravaggio; Carol Borlido; Bruce Pollock; Benoit Mulsant; Vincenzo Deluca; Zahinoor Ismail; David Mamo
Journal:  Psychopharmacology (Berl)       Date:  2013-02-17       Impact factor: 4.530

Review 4.  Clozapine, atypical antipsychotics, and the benefits of fast-off D2 dopamine receptor antagonism.

Authors:  Georges Vauquelin; Sophie Bostoen; Patrick Vanderheyden; Philip Seeman
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2012-02-14       Impact factor: 3.000

Review 5.  Dopaminergic dysfunction and excitatory/inhibitory imbalance in treatment-resistant schizophrenia and novel neuromodulatory treatment.

Authors:  Masataka Wada; Yoshihiro Noda; Yusuke Iwata; Sakiko Tsugawa; Kazunari Yoshida; Hideaki Tani; Yoji Hirano; Shinsuke Koike; Daiki Sasabayashi; Haruyuki Katayama; Eric Plitman; Kazutaka Ohi; Fumihiko Ueno; Fernando Caravaggio; Teruki Koizumi; Philip Gerretsen; Takefumi Suzuki; Hiroyuki Uchida; Daniel J Müller; Masaru Mimura; Gary Remington; Anthony A Grace; Ariel Graff-Guerrero; Shinichiro Nakajima
Journal:  Mol Psychiatry       Date:  2022-04-20       Impact factor: 15.992

Review 6.  Molecular Imaging of Dopamine Partial Agonists in Humans: Implications for Clinical Practice.

Authors:  Xenia M Hart; Christian N Schmitz; Gerhard Gründer
Journal:  Front Psychiatry       Date:  2022-04-06       Impact factor: 5.435

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.